NImmune Biopharma Launches with Phase III-Ready Asset Gained from Landos Biopharma

by | Mar 22, 2023

Virginia life sciences entrepreneur Josep Bassaganya-Riera’s latest company NImmune Biopharma launched with an eye on a potential New Drug Application for its Phase III-ready experimental therapeutic for ulcerative colitis.

NImmune Biopharma’s lead asset is the clinical candidate omilancor, which it secured in February from Landos Biopharma, a company Bassaganya-Riera founded in 2017. Along with omilancor, NImmune gained the rights to Landos’ LANCL portfolio of immunoregulatory therapeutic assets, which also includes assets previously known as LABP-104 and LABP-111. These assets are designed to activate the Lanthionine Synthetase C-Like 2 (LANCL2) pathway, which enhances immunoregulatory processes that provide protection from autoimmune disease. Each of these assets were originally developed by Bassaganya-Riera, who served as chief executive officer of Landos until his departure from the company in November 2021.

Read More >

Recent Releases

Press Release
NImmune Biopharma to Present at DDW’25 the First Ever Head-to-Head Clinical and Translational Results for Omilancor Versus Leading Anti-TL1A in IBD Showing Superiority and Complementarity

NImmune Biopharma to Present at DDW’25 the First Ever Head-to-Head Clinical and Translational Results for Omilancor Versus Leading Anti-TL1A in IBD Showing Superiority and Complementarity

Download Press Release New results affirm omilancor’s ability to safely reverse colonic regulatory T-cell (Treg) depletion and mitochondrial dysfunction in severe UC patients which defines a core subset of patients traditionally refractory to existing approved IBD...

Read More

Press Release
The NIMML Institute and NImmune Biopharma Showcase How the TITAN-X A.I. Platform has Accelerated Therapeutic Development in the Annual Review of Biomedical Data Science

The NIMML Institute and NImmune Biopharma Showcase How the TITAN-X A.I. Platform has Accelerated Therapeutic Development in the Annual Review of Biomedical Data Science

Download Press Release TITAN-X Precision Medicine A.I. Platform identifies therapeutic targets and successfully fueled development of expansible pipelines with leading therapeutic assets in Phase 1-3 clinical testing Integrates A.I., bioinformatics and advanced...

Read More

Press Release
NIMML Institute to Present Novel Clinical and Translational Data of Omilancor in Ulcerative Colitis Patients at Digestive Disease Week 2025

NIMML Institute to Present Novel Clinical and Translational Data of Omilancor in Ulcerative Colitis Patients at Digestive Disease Week 2025

The NIMML Institute, (“NIMML”), a 501 (c)(3) nonprofit institute dedicated to the discovery of novel precision medicines for inflammatory and autoimmune diseases, will present results from two novel studies for omilancor, a once-daily, oral, best- and first-in-class therapy in Phase 3 clinical development for ulcerative colitis (“UC”) and Phase 2 for Crohn’s disease, at  Digestive Disease Week 2025. DDW 2025 will be held at the San Diego Convention Center from May 3-6, 2025.

Read More